Related Experiment Video

Updated: Mar 28, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Statins to improve cardiovascular outcomes in treated HIV infection

Chris T Longenecker1, Allison R Eckard, Grace A McComsey

  • 1aUniversity Hospitals Harrington Heart and Vascular Institute bCase Western Reserve University School of Medicine, Cleveland, Ohio cMedical University of South Carolina, Charleston, South Carolina dUniversity Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.

Current Opinion in Infectious Diseases
|December 15, 2015
PubMed

Insights

Statins may reduce cardiovascular risk in people with HIV by improving vascular inflammation and plaque volume. Potent statins like rosuvastatin and atorvastatin are recommended, considering individual risk assessment.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in people with HIV.
  • Traditional CVD risk calculators may underestimate risk in this population.
  • Modern antiretroviral therapy (ART) has improved HIV management but CVD risk remains elevated.

Purpose of the Study:

  • To evaluate the efficacy of statins in reducing cardiovascular risk among patients living with HIV.
  • To assess the impact of statins on vascular inflammation and plaque progression in HIV-infected individuals.

Main Methods:

  • Review of current evidence on statin use in HIV patients.
  • Analysis of studies examining the effects of atorvastatin and rosuvastatin on coronary plaque and carotid intima-media thickness.
  • Evaluation of potential mechanisms of statin benefit beyond lipid-lowering.

Main Results:

  • Moderate to high-dose atorvastatin and rosuvastatin reduced noncalcified coronary plaque volume and slowed carotid intima-media thickness progression.
  • Lipoprotein changes with statins in HIV patients are similar to the general population.
  • Statin benefits may involve improvements in vascular inflammation and immune cell activation; rosuvastatin may increase insulin resistance.

Conclusions:

  • Statins are likely beneficial for cardiovascular outcomes in patients with HIV.
  • Individualized risk assessment is crucial for statin prescription in this population.
  • Potent statins (rosuvastatin, atorvastatin, pitavastatin) are recommended when appropriate, pending outcome study results.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
419
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
319